ERBB2 and breast carcinoma: ECLIPSE trial (ClinicalTrials.gov Identifier: NCT03395899) is an example, in which Atezolizumab and Cobimetinib were given with Bev in an arm for women with untreated, histologically confirmed, operable, ER+, HER2-negative breast cancer.